P899 - THERAPEUTIC EFFECTS OF GLUCAGON LIKE PEPTIDE (GLP)-1 RECEPTOR AGONISTS IN HIDRADENITIS SUPPURATIVA: A RETROSPECTIVE STUDY

P899

THERAPEUTIC EFFECTS OF GLUCAGON LIKE PEPTIDE (GLP)-1 RECEPTOR AGONISTS IN HIDRADENITIS SUPPURATIVA: A RETROSPECTIVE STUDY

R. Thibault^1,2,*, L. Gouvrion³, M. Delage ⁴, A. Villani ⁵, S. Le Naour ⁶, C. Fite ⁷, C. Cassius ⁸, L. Misery ⁹, A. Brun ¹⁰, A. Fayad¹¹, B. Oules ¹², C. Pruvsot-Balland ¹³, G. Safa ¹⁴, M. Tardieu ¹⁵, S. Buche ¹⁶, A. Maruani ¹⁷, G. Quereux⁶, A. Nassif⁴, A. Guenego ¹, A. Dupuy ³, F. Poizeau³

¹Endocrinology-Diabetology_Nutrition, CHU Rennes, ²Nutrition Metabolisms and Cancer, univ Rennes, INRAE, INSERM, ³Dermatology, CHU Rennes, Rennes, ⁴Centre Médical, Institut Pasteur, Paris, ⁵Dermatology, Hôpital Edouard Herriot, Lyon, ⁶Dermatology, CHU Nantes, Nantes, ⁷Dermatology, Hôpital St Joseph, ⁸Dermatology, Hôpital St Louis, Paris, ⁹Dermatology, CHU Brest, Brest, ¹⁰Dermatology, CHU Toulouse, Toulouse, ¹¹Dermatology, CHU Angers, Angers, ¹²Dermatology, Hôpital Cochin, Paris, ¹³Dermatology, CH Vannes, Vannes, ¹⁴Dermatology, CH St Brieuc, St Brieuc, ¹⁵Dermatology, CHU Grenoble, Grenoble, ¹⁶Dermatology, CHU Lille, Lille, ¹⁷Dermatology, CHRU Tours, Tours, France

Rationale: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease, associated with obesity. GLP-1 receptor analogs (RAs) may have a therapeutic effect on HS. Objectives: to describe the impact of GLP-1RAs (semaglutide (S), liraglutide (L) or dulaglutide (D)) on HS severity.

Methods: Multicenter (n=15 centres), retrospective study of HS patients exposed to GLP-1-RAs. Inclusion: national case recruitment and data repositories. L and S (greater effects on glucose control and weight loss) were compared to D. The physician's global assessment of HS (HS-PGA) clinical severity score, flare-up frequency, pain, suppuration, quality of life, were measured at the start of GLP-1RA (T0), after 6 mo (M6), and at GLP-1RA treatment discontinuation or the last follow-up visit (Tmax). Primary endpoint: HS improvement, i.e. reduction in the HS-PGA score between M6 and T0. Univariate and multivariate logistic regression models were performed to identify factors associated with HS improvement.

Results: 66 patients (S, n=48, D, n=13, L, n=5) were included, median follow-up of 18.5 mo, and BMI of 39.4; 86.4%, type 2 diabetes, 92.4%, obese. 53.8% improved from HS at M6, 60.3% had less relapses. Compared with D, L or S was significantly and strongly associated with improvement in HS (OR=13.1, 95% CI (2.3-116.3)), after adjustment for age, sex, smoking, year of GLP-1RA initiation, concomitant HS treatments. There was no association between HS improvement and S or L dose (OR=1.04, 95% CI (0.22-5.68). Weight reduction was greater at Tmax with S and L vs D (mean weight reduction of 11.7 kg vs. 5.0 kg, p=0.006). No association between HS improvement and weight loss (OR=0.99, 95% CI (0.94-1.04)).

Conclusion: This is the 1^st study to report the effect of GLP-1-RAs in HS. Liraglutide and semaglutide may have a place in HS therapy and not through weight loss. A randomized, placebo-controlled trial is needed.

Disclosure of Interest: None declared